SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XNVAY or XEN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Michael de Haan who wrote (6)1/28/1997 9:49:00 PM
From: James Silverman   of 28
 
Michael,
Its not much of an analysis, admittedly I bought shares largely on speculation on the belief that the MetaXen subsidiary would speed up their business plan and help establish corporate partners in short order and at the price of a week or so ago, we were looking at a $75M market value and $52M cash on hand. Seemed an absurdly low price for what looks to be solid science. Other than that, I really am in the dark as to how the compounds in clinicals are looking, or how advanced the Metaxen platform is-I have heard it is solid, but thats second hand.

If you could expand upon what you know about the leadership of Xenova, I would appreciate it. You know these biotechs-a solid CEO is crucial.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News